Longevity & AgingNew Drug AT7687 Boosts Weight Loss Beyond Leading Obesity Treatment in Early Trials
A new experimental drug called AT7687, developed by Antag Therapeutics, showed promising safety and early effectiveness in a Phase 1 trial involving 102 participants. The drug was well tolerated with no serious side effects and minimal gastrointestinal issues. When combined with cagrilintide — an existing obesity drug — AT7687 helped obese, insulin-resistant primates lose 12.2% of body weight compared to 7.8% with cagrilintide alone, while also improving insulin sensitivity. The drug is designed for once-weekly injection. Antag has secured €80 million in funding and plans to begin a Phase 2a human trial in mid-2026. For those tracking obesity and metabolic health science, this represents a potentially meaningful addition to the growing toolkit of weight-loss therapeutics.
